Search PubMed⌕ Search

Biomedical subjects

M Tsirantonaki

Publications and source records attributed to M Tsirantonaki.

9 recordsLinked to original sources
PubMed1998

Pyomyositis.

A case of non-tropical pyomyositis (PM), in a 63-year-old female patient, affecting gluteus and intrapelvic muscles is presented. Delayed diagnosis and treatment led to long-standing morbidity. Magnetic resonance imaging (MRI) of the pelvis provided valuable information on the nature and extent of the disease and helped to plan surgical management. MRI of the pelvis should be undertaken at an early-stage. Prompt examination of material obtained by aspiration or debridement would then permit an accurate diagnosis and appropriate management.

Anti-Bacterial Agents↗
PubMed1996

Value of ascitic fibronectin and cholesterol concentration in the differentiation between malignancy-related and non-malignant ascites.

In this prospective study, we tried to evaluate various "humoral tests of malignancy" regarding their efficiency of discriminating between malignancy-related and non-malignant ascites. Fibronectin, total protein, number of cells, LDH, pH, specific gravity and cytology were compared in the ascitic fluid of 51 patients with malignancy-related and 52 patients with non-malignant ascites; patients with tuberculous peritonitis were not included. Ascitic fluid cholesterol was determined in 36 of 51 malignancy-related and in 37 of 52 non-malignant ascites. Cytology and fibronectin were found 100% specific with diagnostic efficiency 87.5% and 94.2% respectively under optimal conditions. Cholesterol was neither sensitive nor specific. It is concluded that fibronectin was a valuable test for malignancy-associated ascites.

Ascitic Fluid↗
PubMed1995

Significance of various factors in patients with functional dyspepsia and peptic ulcer disease in Greece. A comparative prospective study.

This prospective study was undertaken to evaluate the significance of factors such as age, sex family history, educational status, residence area, H pylori antral colonization, smoking, alcohol consumption, coffee and cola drinking in Greek patients suffering from functional dyspepsia (FD), duodenal ulcer (DU), and gastric ulcer (GU). The study groups were chosen among consecutive outpatients who had undergone an upper gastro-intestinal (GI) endoscopy during a ten-month period because of dyspepsia, and who completed a suitable questionnaire; 295 patients aged 18-85 years (M: 185, F: 110) were finally included as follows: 54 patients aged 18-80 years M: 21, F: 33) with FD, 166 aged 19-85 years (M: 117, F: 49) with DU, and 75 aged 24-85 years (M: 47, F: 28) with GU. As controls for FD patients, 54 previously studied, healthy non-dyspeptic people, well matched for age and sex, were used. No differences were found between them and FD patients. On the contrary, we found that the 3 groups of patients differed significantly for age (p = 1.07 x 10(-3)) and sex (p = 1.67 x 10(-4)) distribution. There was a rather even age distribution and a discrete female predominance in the FD group. Positive family history for peptic ulcer disease (PUD) was found in 19% of patients with FD as compared with 48.2% (DU) and 37% (GU) (p = 4.84 x 10(-4)). Significantly more patients with PUD were smokers (p = 6.16 x 10(-3)) and alcohol drinkers (p = 1.84 x 10(-4)). H pylori antral colonization was found in 61% of patients with FD as compared with 74% (GU) and 85% (DU) (p = 8.65 x 10(-4)) of patients. Finally, factors such as educational level, area of residence, and cola drink consumption did not differ in the studied groups of patients.

Adult↗
PubMedDate not supplied

High eradication rate of Helicobacter pylori using a four-drug regimen in patients previously treated unsuccessfully.

The objective of this study was to assess the efficacy of a new regimen in eradicating Helicobacter pylori (Hp) in patients with duodenal ulcer (DU) who were previously treated unsuccessfully with standard triple therapy (tripotassium dicitratobismuthate [TDB] 120 mg QID, metronidazole 500 mg TID, and tetracycline 500 mg QID) or proton-pump inhibitor (PPI) dual therapy (omeprazole 20 mg BID and amoxicillin 500 mg QID). The study included 133 consecutive patients aged 17 to 83 years with endoscopically diagnosed DU (diameter > or = 5 mm) in whom standard triple therapy or PPI dual therapy had failed to eradicate Hp. A rapid urease (CLO) test was performed on four biopsy specimens at study entry and at least 1 month after the end of treatment to confirm Hp colonization and eradication, respectively. Patients were considered to be Hp positive if any CLO test was positive within 2 hours, and Hp was considered to be eradicated if all CLO tests were still negative after 24 hours. In 31 randomly selected patients, Hp eradication was confirmed histologically as well. Patients were given omeprazole 60 mg/d (20 mg in the morning and 40 mg in the evening) plus amoxicillin 500 mg QID for 10 days and subsequently were given metronidazole 500 mg TID for 10 days plus TDB 120 mg QID for 6 weeks. One hundred and twenty-four patients were followed up; five (4%) withdrew because of side effects (protracted diarrhea, stomatitis, skin rashes). Per-protocol analysis showed Hp eradication in 113 of 119 patients (95%) and ulcer healing in 118 of 119 (99%). Intent-to-treat analysis showed an Hp eradication rate of 85% (113 of 133 patients) and an ulcer healing rate of 89% (118 of 133 patients). In per-therapy analysis, the Hp eradication rate was 91% (113 of 124 patients), and the ulcer healing rate was 95% (118 of 124 patients). Side effects were observed in 39 of 119 patients (33%) and were generally mild. The four-drug regimen used in this study, when given to patients previously treated unsuccessfully with standard triple therapy or PPI dual therapy, was highly effective in eradicating Hp and healing DUs and had no major side effects.

Adolescent↗